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Background: The risk of depression is high for cancer patients and a large portion of cancer
patients are age 65 and over. Both depression and cancer are economically burdensome and
depression is associated with healthcare expenditure increase for elderly patients. However,
whether comorbid depression affects healthcare expenditures in elderly cancer patients from
payers’ and patients’ perspectives is largely unknown. Objective: To investigate whether
depression is associated with higher healthcare expenditure among elderly cancer patients
from both payers’ and patients’ perspectives and, and determine whether depression is
associated with higher probability of having high out-of-cost burden. Methods: From the
Medicare Current Beneficiary Survey (MCBS)-Medicare database, we identified breast, lung
and prostate cancer patients aged 65 years or older who were newly diagnosed between 2007
and 2012 using Medicare claims. Presence of depression was based on self-reports from the
surveys. Healthcare expenditures included expenditures incurred in the cancer diagnosis year
and the subsequent calendar year. High out-of-cost burden was referred to as out-of-pocket
cost as over 10% of respondent’s income. For the analyses of healthcare expenditures,
generalized linear models (GLM) and two-part models were used to examine the impact of
depression on healthcare expenditures when controlling for all other covariates assessed in

the study. We stratified the analyses by healthcare service types and payers. For the analyses
of high out-of-pocket cost burden, logistic regression was used to estimate whether
depression was associated with higher probability of having high out-of-pocket cost burden.
Results: Of the 710 elderly breast, lung and prostate cancer patients identified, 128 (18%)
reported depression. The results revealed that elderly cancer patients with depression had
$11,454 higher overall total healthcare expenditures. From Medicare’s perspective, elderly
patients with depression incurred $8,280 higher expenditures, $4,327 higher medical
provider expenditures and $870 higher expenditures on other services. They were also more
likely to use inpatient services and other services. From the patients’ perspective, they had
higher healthcare expenditures, medical provider expenditures and other expenditures
($1,270, $654 and $465, respectively). For high out-of-pocket cost burden, although the
unadjusted result was significant, the adjusted result was not. Conclusions: Elderly patients
with depression had significantly higher healthcare expenditures from the payers’
perspective. Although they did not have higher out-of-pocket cost burden, they did have
higher healthcare expenditures from patients’ perspectives and over different expenditure
types. These findings provide compelling evidence for policy makers, physicians and
researchers to develop guidelines for and conduct studies of depression screening, diagnosis
and treatment for geriatric cancer populations.
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BACKGROUND
Statement of the Problem
It has been shown that the risk of depression is higher for cancer patients than those
with stroke, diabetes and heart disease.1, 2 Moreover, many studies have suggested that
patients’ short-term and long-term physical and mental health are negatively impacted by the
coexistence of cancer and depression. 3-5Therefore, understanding the mental health need
among cancer patients is a vital task to improve holistic wellbeing for cancer patients.
Additionally, as a result of the aging population in the United States and the high prevalence
of cancer among the elderly, the majority of cancer survivors is 65 and over; it is projected
that, by 2040, 73% of 26.1 million cancer survivors will be 65 years or older.6 Considering
the serious negative impact of coexisting depression on cancer patients, it is important to
study the association between cancer and depression among the elderly.
This study focuses on three most prevalent cancers: breast cancer, lung cancer and
prostate cancer. In particular, prostate cancer is the most prevalent among males, and breast
cancer is the most prevalent among females. Lung cancer ranks the second in both males and
females.7 The goal of the study is to understand the economic impact of depression on elderly
cancer patients through these three important types of cancers.
As one of the most economically burdensome disorders, depression is usually
associated with excess healthcare expenditures. In particular, it has been shown that
depression is associated with increase in direct health care costs for the elderly patients with
depression. 8, 9However, the healthcare expenditures of depression, in addition to cancer
1

itself, from the perspective of both payers and patients is largely unknown for elderly cancer
patients, which is a quite unsatisfactory situation.
Therefore, it is vital to study the additional healthcare expenditure of depression
among elderly depressed breast, prostate and lung cancer patients.

Objectives
The overall objective of this study is to estimate the additional healthcare
expenditures of depression for elderly breast, prostate and lung cancer patients with
depression from both the payer and patients’ perspectives. In addition, this study will
examine how elderly depressed breast, prostate and lung cancer patients are adherent on
antidepressant therapy and related factors. In particular, the aims of this study are:
Aim 1. From payer’s perspective, determine if elderly breast, lung and prostate cancer
patients with depression have more healthcare expenditures than those without depression
•

Hypothesis: elderly breast, lung and prostate cancer patients with depression will incur
higher healthcare expenditures than those without depression in payer’s perspective
Aim 2. From patients’ perspective, determine if elderly breast, lung and prostate

cancer patients with depression have more out-of-pocket healthcare expenditures than those
without depression
•

Hypothesis: elderly breast, lung and prostate cancer patients with depression will incur
higher out-of-pocket healthcare expenditures than those without depression

2

Aim 3. Determine if elderly breast, lung and prostate cancer patients with depression
are more likely to have high out-of-pocket cost burden than those without depression
•

Hypothesis: depression will be significantly associated with increased odds of high outof-pocket cost burden

Public Health Significance
There is a high prevalence of depression among elderly cancer patients. Considering
the fact that cancer and depression is each associated with very high expenditures, it is
important to study the healthcare expenditures when the two coexist, which is not clear from
existing studies. The result of the Aims 1 and 2, by examining the overall health expenditures
from both payer and patients’ perspectives will bridge this important gap in the literature.
Additionally, the result will increase the awareness of depression issues for elderly cancer
patients and help evaluate relevant depression prevention/management interventions for this
population. Also, the expenditure estimates can be used in cost-effectiveness studies of
interventions addressing depression for elderly cancer patients: the reduction of depression
related healthcare costs would partially offset the intervention costs. The result of Aim 3,
examining whether depression is associated with a high out-of-pocket cost burden, will
strengthen the importance of studying individual financial burden for this population.

3

Literature Review
High Proportion of Elderly Patients with Breast, Lung and Prostate Cancer
It is estimated that 62% of the cancer survivors living in the U.S. are 65 years or older
in 2016. By 2040, the proportion of elderly cancer survivors will grow to 73% and the
absolute number will become close to 30 million.6 Like most cancers, breast, lung and
prostate cancers are diseases of the elderly people. In the U.S., the median age of diagnosis is
about 62 for female breast cancer, 68 for male breast cancer;10 70 for lung cancer and 66 for
prostate cancer.10 Such high concentration of cancer among the elderly reinforces the
importance of understanding how this disease affects the overall clinical and economic
wellbeing of this population. This paper is specifically interested in exploring the intersection
of cancer and depression among those 65 and older.
High Prevalence of Depression among Breast, Prostate and Lung Cancer Patients
Cancer often places significant psychological burdens on patients not only at the time
of diagnosis but also during treatment and afterwards. Indeed, many studies show that cancer
patients are more likely have depression.11-13 Furthermore, depression symptoms of cancer
patients are frequently ignored by clinicians and viewed to be the normal psychological
reactions of cancer diagnosis and treatments. It has been shown that detection rate of
depression is low among cancer patients and the rate of depression is often underestimated.
14, 15

For example, in a large study of over 1,100 cancer patients, physicians only correctly

identified 33% of patients with mild to moderate depression, and only 13% of patients with
severe depression were diagnosed.15 As a result, the actual rate of depression among cancer
patients are likely to be higher than the reported numbers in existing studies.
4

Breast, prostate and lung cancers are all highly associated with depression and
depression can appear at any time during the course of the cancers. For example, a study
reported the prevalence of depression among breast cancer patients ranged from 1.4% to
46%. 16 For lung cancer, it is also reported that about 11% to 44% of lung cancer patients
suffered from depression.16 In a study estimating longitudinal changes in depression
symptoms, 38% had depression symptoms at baseline and 14% more developed “new-onset
depression symptoms” during treatment.17 For prostate cancer, “the lifetime prevalence of
major depressive disorder in adults in the U.S.” is 17%. 18An article identified 50,147 elderly
patients with newly diagnosed prostate cancer found that 8.54% of them were diagnosed with
depression following their prostate cancer diagnosis. 19A meta-analysis identifying 27 journal
articles and with a pooled sample size of 4,494 prostate patients identified pre-treatment, ontreatment and post-treatment depression prevalence of 17.27%, 14.70% and 18.44%,
respectively.20
Negative Impact of Depression on Breast, Lung and Prostate Cancer Patients
Depression has negative impact on many aspects of cancer patients’ outcomes. For
example, depression has been linked to higher mortality, poorer quality of life, and poorer
treatment adherence for cancer patients in general. 3-5
Similar negative impact of depression has been found on breast, lung and prostate
cancer. For example, a study found that breast cancer patients with depression had lower
overall quality of life. 21Additionally, depression reduces likelihood of breast cancer patients’
adherence to their medical treatments.21, 22
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For lung cancer, it has been shown the depression affected the functional status
negatively. 23Also, depression has been shown to decrease survival among patients recently
diagnosed lung cancer.24
For prostate cancer, depression also reduces treatment effectiveness, and lowers the
survival.25
High Healthcare Expenditures of Breast, Lung and Prostate Cancer and Depression
Depression is one of the most economically burdensome disorders worldwide.
Moreover, studies have suggested that the already excessive healthcare cost of depression has
increased rapidly in recent years; the extra economic burden for patients with major
depressive disorder had increased by 21.5% from 2005 to 2010 in the U.S..26, 27
It is also well-known that cancer is a very expensive disease for both the patients and
the society as a whole. For instance, a study projected that the cost of cancer in the US would
reach $173 billion in 2020, representing a 40% increase from 2010. In 2010, the annualized
mean net costs of female breast cancer care for elderly patients was $23,078 in initial phase,
$2,207 in continuing phase, and $62,856 in last year of life for cancer death. The annualized
mean net costs of female lung cancer care for elderly patients was $60,533 in initial phase,
$8,130 in continuing phase, and $92,524 in last year of life for cancer death. For male lung
cancer patients, the numbers were $60,885, $7,591 and $95,318, respectively, and for elderly
prostate cancer patients, the numbers were $ 19,710, $3,201 and $ 62,242, respectively. The
national cost of care for female breast cancer patients is $16.50 billion, which is the highest
cost among all cancers. The national costs of care for lung cancer and prostate cancer, $12.12
billion and $11.85 billion, respectively, which rank 4th and 5th among all cancers. It is
6

projected that the national costs in continuing phase for prostate and female breast cancers
would rank the top in 2020.28
Additionally, for breast cancer, a synthesis of published evidence in 2009 estimated
the “lifetime per-patient costs” of breast cancer varied from $20,000 to $100,000.29Also, a
study about the economic burden of lung cancer in 2005 estimated that the overall costs,
from diagnosis to no more than two years after diagnosis, were about $46,000.30 Moreover,
some research estimated lifetime costs for prostate cancer patients enrolled in Medicare at
$110,520 in 2004 U.S. dollars, about 31% of which is prostate cancer-related.31
Additional HealthCare Expenditures of Depression for Breast, Lung and Prostate Cancer
Patients
Although depression is associated with an increase in direct health care costs for
elderly patients with depression8, 9, only a few studies have examined the healthcare
expenditures of depression for cancer patients. In a recent paper about cancer patients aged
21 years and older, a study showed that those with depression had more than 30% greater
one-year healthcare expenditures compared with those without depression. They found
depression increased many types of health care expenditures, including total, outpatient, and
prescription expenditures; depression also increased their emergency service utilization.32
In terms of elderly cancer patients, a paper about prostate cancer showed that among
elderly prostate cancer patients, those with depression had significantly “higher inpatient
pharmacy, physical therapy and laboratory costs in all phases”; additionally, they had higher
medical and surgical supply costs, except for the terminal phase, compared with those
without depression.19
7

Overall, the existing studies either did not examine the overall health care
expenditures including both the payer’s and patients’ perspectives or did not focus on elderly
cancer patients or did not examine multiple types of cancers as this study proposes to do.
Hence, the healthcare expenditures of depression, in addition to cancer itself, from the
perspective of both payers and patients is not studied well for elderly cancer patients.
Conceptual Model
This study utilized an expanded Andersen Behavioral Model as the conceptual
framework.33 Concisely, the model is composed of five main constructs 1) predisposing
factors; 2) enabling factors; 3) need factors; 4) personal health practices and use of health
services; 5) the external environment. As a result of the flexibility of the model, it can be
easily to be applied to analyze the relationship between various patient characteristics,
detection of depression as well as the healthcare expenditures associated with depression.
Variable selection for this study (Figure 1) was guided by published studies34-36 that
adopted the Anderson Behavioral Model while taking into consideration data elements
available in Medicare Current Beneficiary Survey (MCBS)-Medicare. A valuable list of
factors associated with health service utilization for adult cancer survivors are summarized in
a recent review paper on Andersen Behavioral Model. 34Additionally, some studies employed
this model to assess the relationship of different factors and healthcare expenditures35, 36. For
example, a study using Medicaid data examined the “association between depression
treatment and healthcare expenditures among adults with Type 2 Diabetes Mellitus and
depression”, taking “coexisting chronic physical conditions” into account, used this model to
select independent variables other than the main predictor: “gender, race and age” as
8

predisposing factors; “Medicaid eligibility status” as enabling factors; “ mental health
conditions” as individual’s level of need; “healthcare-seeking behaviors and total baseline
healthcare expenditures” as personal health practices and use of health services; “state of
residence, community level healthcare infrastructure and community level social
determinants of health variables” as external environment35. Another study using MCBS
data examined the association between depression treatment and healthcare expenditure also
used this model as the conceptual framework to select variables other than the main
predictor: “gender, race and age” as predisposing factors; “marital status, education, poverty
status, and prescription drug coverage” as enabling factors; “perceived health status and
functional status” as individual’s level of need; “smoking status, body mass index (BMI),
depression treatment, and the baseline year log-transformed health expenditures” as personal
health practices and use of health services; “metro status” as external environment36.
Figure 1: List of Covariates included in the analyses
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Main predictor

Predisposing
Factors

Enabling Factors

Need Factors

Personal health
practices and
use of health
services
External
Environment

•Depression Status

•Age
•Race/Ethnicity
•Gender

•Poverty status
•Supplemental Insurance Type
•Marital status
•Educational Attainment

Outcomes
 Aim 1 & 2: Additional healthcare
expenditures of depression from
both payers’ and patients’
perspectives
 Aim 3: High out of pocket cost
burden

•Perceived health status
•Comorbidities
•Functional Health Status
•Cancer Types

•Body mass index (BMI)
•Smoking Status

•Urban/rural status

10

METHODS
Data Source
The 2007-2013 Medicare Current Beneficiary Survey (MCBS)-Medicare data
sponsored by the Centres for Medicare & Medicaid Services (CMS) was used. The data was
generated by sampling a nationally representative sample of non-institutionalized Medicare
beneficiaries, who are surveyed continuously. The data set had two types of files: Access to
Care (MCBS/AC) and Cost and Use (MCBS/CU). MCBS/CU files linking Medicare claims
to survey-reported events were used. The data set contained comprehensive and detailed
information on patient demographics, socioeconomic status, access to healthcare, healthcare
utilization, and self-reported health status and symptoms, and is linked to the Medicare
claims to the survey.37
Study Design
This was a retrospective cohort study examining Medicare Current Beneficiary
Survey (MCBS) respondents (age>=65) diagnosed with breast, lung or prostate cancer
between January 2007 and December 2012.The study captured depression status based on
self-reports from survey data no later than subsequent follow-up calendar year after cancer
diagnosis and collected their expenditures information between January 2007 and December
2013.

11

Analyses
For Aim1 & 2: Determine if elderly breast, lung and prostate cancer patients with
depression have more healthcare expenditures than those without depression from payer’s
and patients’ perspective, respectively.
First, patient characteristics and healthcare expenditures were compared by patients’
depression status, using the Chi-square tests for categorical variables and t-test for
continuous variables.
Then, this study applied multivariate analysis that included the depression status as one
of the covariates. The presence of depression was defined by two questions in the survey: (1).
were you depressed the last 12 months? (2). did you lose interest the last 12 months? A patient
was considered to have depression if he/she responded positively to both of the questions.
Since healthcare expenditures were highly skewed, the logarithmic transformation with
ordinary least squares (log OLS) regression (ln(𝑌𝑌𝑖𝑖 ) = 𝑋𝑋𝑖𝑖 𝛽𝛽 + 𝜀𝜀𝑖𝑖 .) and a general linear model
(GLM)(𝑙𝑙𝑙𝑙 𝐸𝐸(𝑦𝑦𝑖𝑖 |𝑥𝑥𝑖𝑖 ) = 𝑥𝑥𝑖𝑖 𝛽𝛽) were considered. Compared to log OLS model, GLM has
advantages in the ways that it avoids needing the smearing estimator for retransforming model

estimates of the difference in mean expenditures, and avoids retransformation bias of log OLS
models, so GLM was chosen.
Then, Park test (Diagnostics for variance functions) was used to select one of the GLM
models. The variance functions is below:
𝑣𝑣𝑣𝑣𝑣𝑣(𝑦𝑦𝑖𝑖 |𝑥𝑥𝑖𝑖 ) = 𝛼𝛼[𝐸𝐸(𝑦𝑦𝑖𝑖 |𝑥𝑥𝑖𝑖 )]λ

Because λ = 2 in our study, so gamma model was used.38
12

The change in healthcare expenditures associated with depression were calculated as
the difference between the exponentiation of the sum of the intercept and the parameter
estimate for depression and exponentiation of the intercept. The percent change in healthcare
expenditures associated with depression was calculated as exponentiation of the parameter
estimate for depression minus one (eβ − 1).
When stratifying the analyses by healthcare service types, there were a large number
of zeros for some of the expenditure categories such as inpatient and other health services
categories of Medicare healthcare expenditures. To deal with this issue, two-part models,
logistic models estimated in the first part and GLMs with gamma distribution and log link in
the second part, were also used to estimate adjusted healthcare expenditures.
This study detected multicollinearity issue by computing variance inflation factor (VIF)
to quantify how much the variance is inflated.
All statistical analyses were adjusted for the MCBS complex survey design and
performed by using survey sampling and analysis procedures in SAS Enterprise Guide version
6.1 (e.g., surveyfreq, surveymeans) (SAS Institute Inc, Cary, NC and Stata 14.2(e.g., svy glm)
(StataCorp, College Station, TX)
For Aim 3: Determine if elderly breast, lung and prostate cancer patients with
depression are more likely to have high out-of-pocket cost burden than those without
depression
This study used multivariate logistic regression to estimate significant predictors to
high out-of-pocket cost burden. The equation is below.
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙[𝜋𝜋(𝑥𝑥)] = 𝛽𝛽0 + 𝛽𝛽1 𝑥𝑥1 + 𝛽𝛽2 𝑥𝑥2 + 𝛽𝛽3 𝑥𝑥3 … + 𝛽𝛽𝑖𝑖 𝑥𝑥𝑖𝑖
13

First, patient characteristics were analyzed by patients’ depression status, using the
Chi-square tests. The high out-of-pocket cost burden rate was also compared by depression
status, according to the independent variables of the five factors of the expanded Anderson
Behaviour Model.
Then, this study included all independent variables in the multivariate logistic
regression regardless of the univariate logistic regression results, because these variables are
based on theories and empirical evidence. For independent categorical variables, the reference
group year of cancer diagnosis (2007–2009), gender (male), age in years at diagnosis (65–74)
and race/ethnicity (Non-Hispanic white),marital status (married), educational attainment (less
than high school), poverty status measured as income (inflated to constant 2017 dollars,
adjusting for annual consumer price index for medical care services

39

) to percentage of the

federal poverty level (less than 200%),supplemental insurance coverage type (private
insurance with drug coverage)40,cancer site (lung), perceived health status (excellent/very
good/good), functional status limitations(the number of activities of daily living (ADLs) with
limitations [none limitation]),the number of comorbid health conditions(none or 1 condition).
(current), BMI (underweight or normal),41 and metro status (metropolitan).
This study tested for multicollinearity by computing variance inflation factor (VIF) to
quantify how much the variance is inflated.
All statistical analyses were adjusted for the MCBS complex survey design and
performed by using survey sampling and analysis procedures in SAS Enterprise Guide version
6.1 (e.g., surveyfreq, surveymeans) (SAS Institute Inc, Cary, NC and Stata 14.2(e.g., svy glm)
(StataCorp, College Station, TX)Measurement/Measures
14

In terms of cohort creation, three types of cancer and depression were the key
variables. For depression, the study will define the patient as having depression symptoms
via two questions in the survey: (1). were you depressed the last 12 months? (2). did you lose
interest the last 12 months? A patient was considered to have depression if he/she responded
positively to both of the questions. The combination of these two questions was found to
have 91% sensitivity and 86% specificity in detecting depression in cancer and palliative care
and hence is a good measure of depression presence based on patient self-report.42 The three
types of diagnosed cancers were defined by ICD-9-CM code in Medicare Claims data: breast
cancer (174.x), lung cancer (162.x), and prostate cancer (185.x). The “newly diagnosed”
cases were identified by using a 12-month wash-out period.
Outcome measures and independent variables by specific aims
Aim 1. From payer’s perspective, determine if elderly breast, lung and prostate
cancer patients with depression have more healthcare expenditures than those without
depression
In this aim, the outcome variable was Medicare payments, which was described in
Table 1. Medicare payments included all healthcare services, including inpatient, skilled
nursing facility, hospital outpatient, home health, hospice, prescription drugs, and medical
provider. Payments were measured over the cancer diagnosis year as well as the subsequent
calendar year. The independent variables included depression status and the five factors the
expanded Anderson Behaviour Model, which were controlled for in the analysis and
described in Table 2.

15

Aim 2. From patients’ perspective, determine if elderly breast, lung and prostate
cancer patients with depression have more out-of-pocket healthcare expenditures than those
without depression
In this aim, the outcome variable was out-of-pocket (OOP) expenditures and
described in Table 1. OOP expenditures included all personal expenditures for both Medicare
covered and non-covered healthcare services, including inpatient, skilled nursing facility,
outpatient, medical providers, prescription drugs, home health, hospice and dental services.
OOP expenditures were measured over the cancer diagnosis year and the subsequent calendar
year. The independent variable included depression status and the five factors in expanded
Anderson Behaviour Model, which were controlled in the analysis and described in Table 2.
The components of healthcare expenditures for Aim 1 and Aim 2 are defined in the
following way: Inpatient expenditures are payments for care received for inpatient hospital
events (admissions). Skilled nursing facility are payments for care received for short-term
facility stays. Hospital outpatient expenditures are the payments for services received in
outpatient settings. An outpatient setting means “outpatient department or outpatient clinic of
a hospital”. Inpatient, skilled nursing facility and hospital outpatient expenditures are
payments for the facility costs only. The provider payments would be included in medical
provider expenditures- the payments for services received from medical providers, unless the
medical providers were actually employed by the facility. Medical providers include
practitioners “such as chiropractors, podiatrists, audiologists and optometrists; mental health
professionals such as psychiatrists, psychologists and clinical social workers; therapists such
as physical therapists, speech therapists, occupational therapists, and intravenous and
16

respiratory therapists; other medical practitioners such as nurses and paramedics; and other
places offering medical care, such as clinics, neighborhood health centers, infirmaries and
urgent care centers.” Home health and hospice expenditures are payments for services
received from health professionals in home health and hospice settings. The health
professionals include “nurses, doctors, social workers, therapists and hospice workers”.
Prescribed medicine expenditures are expenses for all prescription medications “except those
provided by the doctor or practitioner as samples and those provided in an inpatient setting.”
Dental expenditures are the payments for dental services.43
Aim 3. Determine if elderly breast, lung and prostate cancer patients with depression
are more likely to have high out-of-pocket cost burden than those without depression
In this aim, the outcome variable was high out-of-pocket cost burden and described in
Table 1. High out-of-pocket cost burden was referred to as out-of-pocket cost as over 10% of
respondent’s income.40, 44 The income question is “what is you and your spouse’s total
income?”, so the income value was divided by two if a respondent reports income for both
himself/herself and the spouse.
The main predictor was depression status. Other potential determinants of high outof-pocket cost burden included the five factors in expanded Anderson Behaviour Model,
which were controlled in the analysis and described in Table 2.

Table 1: Outcome measures
Aim
Measures
Healthcare
Aim 1
expenditures of
payer’s
perspective

Definition
Medicare
payments

17

Measurement
Continuous
variable:2017
Dollars

Aim 2

Aim 3

Healthcare
expenditures of
patients’
perspective
High out of
pocket cost
burden

Patients’ selfreport out-ofpocket
expenditures
Patients’ out-ofpocket cost is
over 10% of the
personal
income40, 44

Continuous
variable:2017
Dollars
Categorical
Variable: Yes or
No

Table 2: Independent Variables
Independent
Definitions
Measurement
Variables
Main Predictor
Depression Status
Patients’ depression
Categorical Variable: Yes
status
or No
Predisposing characteristics
Age Group
Patients’ age group at Categorical Variable: 65cancer diagnosis
74 years old, 75+ years
old
Race/ethnicity
Patients’
Categorical Variable:
race/ethnicity
Non-Hispanic White, ,
other
Gender
Patients’ gender
Categorical Variable:
Male, Female
Enabling Factors
Poverty Status
income (inflated to
Categorical variable: less
constant 2017 dollars, than 200%, greater than or
adjusting for annual
equal to 200%
consumer price index
for medical care
services39 ) to federal
poverty level
Supplemental
Patients’
Categorical Variable:
insurance
supplemental
Private insurance with
insurance
drug coverage; public with
drug coverage; Medical
insurance only; drug
insurance only; None
Marital status
Patients’ marital
Categorical Variable:
status at cancer
Other(Single/separated/div
diagnosis
orced), Married
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Educational
Attainment

Number of
comorbid health
conditions

Cancer Type
Perceived health
status

Patients’ educational
attainment

Categorical Variable: Less
than High School; High
School graduate; Greater
than High School

Need Factors
Patients comorbid
chronic conditions,
including heart
disease, stroke/brain
hemorrhage,
hypertension, diabetes
mellitus, arthritis,
mental disorder other
than depression,
neurological
conditions, and lung
disease
Cancer type
Patients’ perceived
health status

Functional Health
Status Limitations

Categorical Variable:
None or one condition;
more than one condition

Categorical Variable:
Breast, Lung, Prostate
Categorical Variables: fair
or poor, good, very good
or excellent
Categorical Variables:
none, at least one
limitation

Patients’ number of
activities of daily
living (ADLs) with
limitations
Personal health practices and use of health services
Smoking Status
Patients’ smoking
Categorical Variable:
status
Current, Past, Never
Body mass index
Patients’ BMI
Categorical Variable:
(BMI)
under-weight or normal,
overweight, obese
External Environment
Metro status
Indicator of whether
Categorical Variable:
patients living in
metropolitan, nonmetropolitan
metropolitan
Study Cohort

This study considered all Medicare Current Beneficiary Survey (MCBS) respondents
(age>=65) between January 2007 and December 2012; and collected their expenditures
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information between January 2007 and December 2013.The participants in the cohort were
elderly breast, lung and prostate cancer patients (age>=65 years).
The inclusion/exclusion criteria:
Inclusion criteria:
• Respondents newly diagnosed with cancer(breast, lung or prostate) using a one-year
wash-out period and at least 65 years old at the diagnosis between January 2007 and
December 2012
•

Respondents with continuous enrollment in Medicare Part A and Part B

•

Respondents enrolled in Medicare at least 1 year before cancer diagnosis

•

Respondents having “at least 1 inpatient or 2 outpatient or medical provider claims with
a qualifying cancer diagnosis”40

•

Respondents’ outpatient or provider claims have to be at least 30 days apart

Exclusion criteria:
• Respondents with Medicare Advantage Plans
•

Respondents with missing social-demographic information

•

Respondents who resided in long-term care facilities

•

Respondents who were lost follow up during the study period

Sample Size Calculation
To calculate the sample size, a generally accepted power of 0.80, and an alpha level
of 0.05 were used. For Aims 1 and 2, multiple regression sample size calculation in PASS
1545 was used. Other parameters including a total of 22 controlled variables, one tested
independent variable, the squared multiple correlation coefficient assumed by the null
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hypothesis(𝛽𝛽02), squared multiple correlation coefficient where 0.8 power is calculated(𝛽𝛽12 ),
were entered into the sample size calculation for multiple regression in PASS 1545. This

study set 𝛽𝛽02 to 0. Based on the study results, the coefficient of depression status was 0.3, thus

0.09 was used for 𝛽𝛽12 . The result indicated that 106 observations would be sufficient. This

study actually had 710 observations, which is beyond the sample size calculation result; so
the sample size is not a concern here.
For Aim 3, logistic regression sample size calculation in PASS 1545 was used. Other
parameters including the baseline probability at the study population mean(𝑃𝑃0 ), odds ratio ,
one categorical independent variable of interest, percent of N (the percent of sample with

depression in this study),R-Squared of independent variable of interest with other controlled
variables(𝑅𝑅 2 ) were entered into the sample size calculation for logistic regression in PASS

1545. Based on the study results, 𝑃𝑃0 was 0.4, odds ratio was 1.8, N was 20% and 𝑅𝑅 2 was

0.08. The result indicated that 692 observations would be sufficient. This study actually had
710 observations, which is more than the sample size calculation result; so the study has
sufficient sample size here.
Data Collection
For identifying study cohort, this study used data from the Cost and Use files of MCBSMedicare for years 2007 through 2012. This study captured cancer diagnosis using claims and
depression presence using survey part. For healthcare expenditures collection, this study used
data from the Cost and Use files of MCBS-Medicare for years 2007 through 2013. For Aim1,
it examined healthcare expenditures in the year of diagnosis and subsequent calendar year
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using claims. For Aims 2 and 3, it examined out-of-pocket expenditures in the year of diagnosis
and subsequent calendar year using surveys.

Data Management
The de-identified datasets were stored on the secure server in University of Texas
MD Anderson Cancer Center and the data was stored on a secured and encrypted format. The
desktop was protected by strong security systems in University of Texas MD Anderson
Cancer Center.
All statistical analyses were conducted in SAS Enterprise Guide 6.1 (SAS Institute,
Cary NC) and/or Stata version 14 (Stata Corporation, College Station, TX). This study was
reviewed by the Institutional Review Board (IRB) at University of Texas School of Public
Health to ensure appropriate study design and data management.

Human Subjects, Animal Subjects, or Safety Considerations
The MCBS Data is a de-identified data. Hence, this research qualifies for minimal risk.

Summary and Implications
There were some limitations associated with the data and study design. First, MCBS
data was not linked to cancer registry data, so this used medical claims to identify different
cancer types, which might cause potential misclassification. Second, some information such
as out of pocket payments were based on self-report, which might be subject to recall bias.
However, MCBS data has been considered as a principle resource for assessing out of pocket
cost for Medicare beneficiaries, which is a reliable resource for this study.40 Moreover,
22

MCBS has taken some measures to minimize the recall bias: for example, the respondents
are requested to take their facilitating records of all their healthcare events to the interviews.
Third, this study was an observational retrospective cohort study, which may have
unmeasured confounding factors than cannot be controlled for.
In terms of implications, the study evaluated the additional health care expenditures
of depression in both payer and patients’ perspective and estimate the high out-of-pocket
burden among elderly cancer patients. The key findings of this study, not previously
documented in other studies of elderly Medicare beneficiaries with cancer and depression,
will allow us to better understand the impact of depression on elderly cancer patients. By
estimating the additional healthcare expenditures associated with depression for elderly
cancer patients and identifying the population with cancer and depression who are at risk of
high out-of-pocket cost burden, this study will not only promote the awareness of the
psychological needs of elderly cancer patients among all stakeholders, such as policy makers,
clinicians, patients and their families, but also further the progress of targeted interventions to
improve depression management and evaluations of depression-relevant interventions for this
population.

Timeline
Task

Month in 2018
1

2

Proposal Writing and Defense
IRB Approved
Data Clean and Merge
Data Analysis
Dissertation Writing
Dissertation Defense
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3

4

5

6

7

8

9

10

11

12
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JOURNAL ARTICLE – 1
Association between depression and healthcare expenditures among elderly cancer
patients

Introduction
Studies have shown that the risk of depression is higher for cancer patients than for those with
stroke, diabetes and heart disease.1,

2

While the reported prevalence of depression among

cancer patients has varied by study design and definitions of depression, a previous metaanalysis reported a pooled mean prevalence ranging from 8% to 24%.3 Moreover, cancer
patients’ short-term and long-term physical and mental health are negatively impacted by
depression comorbidity, as depression has been linked to higher mortality, poorer quality of
life, and poorer treatment adherence for cancer patients in general.4-6 Additionally, as a result
of the aging population in the United States and high prevalence of cancer among the elderly,
a large portion of cancer patients are 65 and over; it is projected that by 2040 approximately
70% of those diagnosed with cancer will be 65 years or older.7 Therefore, addressing the
mental health needs of elderly cancer patients is vital to improve the wellbeing of both this
population and society as a whole.
In addition to being one of the most economically burdensome disorders overall, depression is
usually associated with excess healthcare expenditures. In particular, it has been shown that
depression is associated with increased direct healthcare costs for elderly patients with
depression.

8, 9

However, only a few studies have examined the healthcare expenditures of

depression for cancer patients.
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One paper focusing on the nonelderly military population showed that military healthcare
beneficiaries with both cancer and depression had significantly higher annual healthcare costs
compared with those who only had cancer ($16,212 vs $7,728). Moreover, patients with cancer
and depression also had more inpatient, outpatient and medication services utilization.10 A
recent paper about adult cancer patients aged older than 21 years, showed that compared with
those without depression, those with depression had about 32% greater one-year total
healthcare expenditures including all third-party payments and out-of-pocket expenditures by
patient or family. In particular, depression increased many types of healthcare expenditures,
such as total, outpatient, and prescription expenditures for cancer patients. But this paper did
not stratify the analyses by payers.11 A more recent paper from the University of California
San Diego Healthcare System, examining healthcare charges for cancer patients in the first
year after diagnosis, found that depressed individuals had 113% higher total annual healthcare
charges compared to those without depression.12
In terms of the impact of depression on elderly cancer patients’ healthcare expenditure, a study
examining the association of depression with increased healthcare costs among prostate cancer
patients, showed that those with depression had about 30% higher costs compared with those
without depression from Medicare’s perspective during the year after cancer diagnosis.13 Also,
patients with depression had more hospitalization, outpatient and emergency services
utilization.
Limitations of existing studies include failure to examine overall healthcare expenditures
stratified by payers’ and patients’ perspectives, or failure to focus on elderly cancer patients;
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most did not examine multiple cancer types. Hence, the healthcare expenditure associated with
depression in the context of multiple cancer types from the perspective of both payers and
patients is not well studied for elderly cancer patients.
Methods

Conceptual framework
This study utilized an expanded Andersen Behavioral Model as the conceptual framework.14
The model is composed of five main constructs: 1) predisposing factors, which include gender,
race/ethnicity, age at diagnosis and year of cancer diagnosis; 2) enabling factors, which include
supplemental insurance type, marital status, educational attainment and poverty status; 3) need
factors, which include number of comorbidities, cancer site, perceived health status and
functional status; 4) personal health practices and use of health services, which include
smoking status and body mass index (BMI); and 5) external environment, measured as metro
status in this study.
Study design
This is a retrospective cohort study that examined the healthcare expenditures associated with
depression for elderly cancer patients. In this study, we identified cancer diagnosis based on
Medicare claims between January 2007 and December 2012; captured depression status based
on self-reports from survey data either in the year of cancer diagnosis or the subsequent
calendar year; and measured healthcare expenditures in the year of diagnosis and subsequent
calendar year after cancer diagnosis.
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Data source
This study used 2007-2013 Cost and Use files of Medicare Current Beneficiary Survey
(MCBS)-Medicare sponsored by the Centers for Medicare & Medicaid Services (CMS).
MCBS-Medicare is generated by sampling a nationally representative sample of Medicare
beneficiaries, who are surveyed up to three rounds per year for four successive years. The data
set contains two types of files that are released annually: Access to Care (MCBS/AC) and Cost
and Use (MCBS/CU). The MCBS/CU files were used because they link Medicare claims to
survey-reported events. Therefore, the data contains “complete expenditure and source of
payment data on all healthcare services,” even if the services are not covered by Medicare.
Additionally, the data set contains comprehensive and detailed information on patient
demographics, socioeconomic status, healthcare utilization, and self-reported health status and
symptoms.15
Ascertainment of study cohort
The algorithm to identify cancer patients was based on clinical diagnoses in claims. The
beneficiaries were considered to be diagnosed with cancer based on the International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) (140-172, 174208, 225, 227.3 and 227.4) and were required to have at least one inpatient or two outpatient
claims or medical provider claims with a cancer diagnosis based on the ICD-9-CM codes. The
service date between the two outpatient claims was required to be at least 30 days.
Additionally, all patients included in the analytical sample had to be continuously enrolled in
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Medicare Parts A and B without Medicare Advantage enrollment and not reside in a long‐term
care facility during the study period so as to ensure the completeness of Medicare claims and
prescribed medicine event (PME) files. Patients who were lost to follow-up during the study
period were excluded. Newly diagnosed cases were identified by using a 12-month wash-out
period.
If clinical diagnosis codes indicated more than one cancer site, this study applied a hierarchical
process to assign beneficiaries to the cancer site that is more likely to have been the primary
tumor location. For instance, a patient with diagnosis codes for both lung and brain cancer
would be assigned to the lung cancer group. 16, 17 Lastly, this study only included beneficiaries
belonging to groups of breast, lung and prostate cancer sites with ICD-9-CM codes as 174.x,
162.x, and 185.x, respectively.
Identification of depression
This study defined the patient as having depressive symptoms via two questions in the survey:
(1). “In the last 12 months, how much of the time did you feel sad, blue or depressed? “(2). “In
the last 12 months, have you had 2 weeks or more when you lost interest or pleasure in the
things that you usually cared about or enjoyed?” A patient was considered to have depression
if he/she responded “all of the time” or “most of the time” to the first question, and/or answered
“yes” to the second question.18, 19 The combination of these two questions was found to have
91% sensitivity and 86% specificity in detecting depression in cancer and palliative care and
hence is a good measure of the presence of depression based on patient self-report.20
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Dependent variables
The dependent variables included total healthcare expenditure, healthcare expenditure by
service types, and payer types. The total healthcare expenditures were combined by MCBS
from all payers’ payments and respondents’ out-of-pocket (OOP) payments, and include
payments for different services types, including prescribed medicines, dental, home health,
hospice, hospital inpatient, skilled nursing facility, medical provider, and hospital outpatient.
In addition to total healthcare, we also analyzed subtypes of expenditures by healthcare
services and payers. The healthcare services included inpatient (hospital inpatient and skilled
nursing facility), hospital outpatient, medical providers, prescribed medicines, and other (i.e.,
home health, dental, and hospice). The payers included Medicare, other third-parties (i.e., other
public [Medicaid, Veterans Affairs Health Insurance], individually purchased insurance,
employer-sponsored insurance, and other payments) and patients’ OOP expenditures. The
expenditures were inflated to constant 2017 dollars, adjusting for annual consumer price index
for medical care services.21
The measurement period for expenditures included the year of diagnosis and subsequent
follow-up calendar year after cancer diagnosis. While it would have been ideal to measure
expenditures in the 12 months following cancer diagnosis, some expenditures include service
types and payers that are only reported on an annual basis, such as dental services, OOP costs
and other third-party payers.
Other independent variables
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Besides depression status, the other independent variables belonging to the five constructs in
the expanded Andersen Behavioral Model were also identified by self-reports from the survey
data. Predisposing characteristics were: year of cancer diagnosis (2007–2009; 2010–2012),
gender (female; male), age in years at diagnosis (65–74; 75 and over) and race/ethnicity (NonHispanic white; other). Enabling characteristics included marital status (married; other),
educational attainment (less than high school; high school; greater than high school), poverty
status measured as income inflated to constant 2017 dollars, adjusting for annual consumer
price index for medical care services 21 and converted to percentage of the federal poverty level
(less than 200%; greater than or equal to 200%) and supplemental insurance coverage type
(private insurance with drug coverage; public with drug coverage; medical insurance only;
drug insurance only; none)17. Need characteristics included: cancer site (breast; lung; prostate),
perceived health status (excellent/very good/good; fair/poor), functional status limitations(the
number of activities of daily living (ADLs) with limitations [none limitation; ≥1 limitation])
and the number of comorbid health conditions, including heart disease, stroke/brain
hemorrhage, hypertension, diabetes mellitus, arthritis, mental disorder other than depression,
neurological conditions, and lung disease (none or 1 condition;>1 condition). Personal health
practices and use of health services included smoking status (current; past; never), BMI
(underweight or normal, defined as BMI <25 kg/m2; overweight, defined as BMI ≥25- 29.9
kg/m2; obese/morbid obese, defined as BMI ≥ 30 kg/ m2).22 External environment was
captured by metro status (metropolitan; non-metropolitan).
Statistical analyses
36

The chi-square test for categorical variables and t-test for continuous variables were used to
analyze patient characteristics and healthcare expenditures by patients’ depression status; the
tests were weighted using cross-sectional sampling weights.23 To estimate different types of
adjusted additional expenditures associated with depression, generalized linear model (GLM)
regressions with gamma distribution and log link, determined by modified park test24, were
used. This approach has an advantage compared to log-cost regression (log OLS model) in the
way that it evaluates transformation of the difference in mean cost, and avoids retransformation
bias of log OLS models24. In the regression analysis, depression status and all other
independent variables were included.
In the analysis of healthcare expenditure by service types and payer types, we observed a large
number of zeros for some of the expenditure categories such as inpatient and other health
services categories of total healthcare expenditures. When the proportion of zero expenditures
was non-negligible, we adopted two-part models

24

with multivariable logistic regressions in

the first part and GLMs with gamma distribution and log link in the second part. The first part
modeled the probability of utilizing certain services, and adjusted odds ratios (AOR) and 95%
confidence intervals (CIs) were provided. The second part estimated the adjusted effect of
depression among those who had non-zero expenditures.
All statistical analyses were accounted for the MCBS complex survey design and were
performed by using survey sampling and analysis procedures (e.g., surveyfreq, surveymeans)
in SAS Enterprise Guide version 6.1 (SAS Institute Inc, Cary, NC) and Stata 14.2 (e.g., svy
glm) (StataCorp, College Station, TX).
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Results
The sample included 710 elderly beneficiaries who were newly diagnosed with breast, lung
and prostate cancer, among which 128 (17.7%) had depression. The description of the study
sample by depression status is provided in Table 1. Statistically significant differences were
found with respect to supplemental insurance, perceived health status, functional status, and
number of comorbid health conditions. Specifically, patients with both public insurance and
drug coverage were more likely to report depression (35.8%) compared with those with both
private insurance and drug coverage (16.9%), medical insurance only (13.9%) and other
supplemental insurance (18.1%). More patients perceiving fair/poor health status reported
depression (32.7%) compared with those perceiving excellent/very good/good health (13.6%).
Additionally, patients with at least one functional status limitation were more likely to report
depression (35.7%) compared to those with no limitations (15.1%); and those with more than
one comorbid health condition were more likely to report depression (20.9%) compared with
those with none or one comorbid condition (11.1%).
In Table 2, unadjusted total healthcare expenditures were compared between the patients with
depression and those without, presented as total overall expenditures and stratified by service
types and payers. For the categories of expenditures containing zeros, the comparison were
also performed among the patients with non-zero expenditures. Overall, the total healthcare
expenditure was significantly higher for patients with depression ($70,918 vs $44,106). In
analyses stratified by healthcare service types, patients with depression spent significantly
more in medical provider services ($25,052 vs $16,068). Regarding users of other services,
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those with depression also spent significantly more ($8,653 vs $3,559). In analysis stratified
by payers, patients with depression had significantly more Medicare payments ($48,875 vs
$28,856). Additionally, Medicare and OOP expenditures — representing the most important
payer and patient perspectives, respectively — were compared between the two groups by
service types. In sub-service type analyses for Medicare healthcare expenditures, patients with
depression had significantly more medical provider expenditures ($15,566 vs $10,832) and
other services expenditures in beneficiaries who used these services ($12,218 vs $7,077). In
sub-service type analyses for OOP healthcare expenditures, patients with depression had
significantly more medical provider expenditures ($3,028 vs $1,903).
Tables 3-5 provides results from adjusted regressions controlling for all the independent
variables described in the methods section. Table 3 presents the adjusted total healthcare
expenditures and percent change associated with depression from GLM and two-part models,
overall and stratified by service types and payers. The results showed that significant
differences were found in total healthcare expenditures and also in some total expenditure
categories. Patients with depression had $11,454 higher total healthcare expenditures, which
corresponded to 34.5% greater total healthcare expenditures. Among different service types,
patients with depression had 45.9% higher medical provider expenditures and were
significantly more likely to have inpatient services (AOR, 2.94; 95% CI, 1.82–4.74) compared
with those without depression. In users of other services, patients with depression had 50.1%
greater other services expenditure. In terms of payers, patients with depression not only
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incurred $8,280(43.8%) more expenditures from Medicare’s perspective, but also
$1,270(32.9%) higher expenditures from patients’ perspective.
Adjusted Medicare healthcare expenditures and percent change associated with depression
from GLM and two-part models stratified by service types are presented in Table 4. From
Medicare’s perspective, among different healthcare services, patients with depression had 36%
higher medical provider healthcare expenditures. Patients with depression were highly
significantly more likely to use inpatient services (AOR, 2.7; 95% CI, 1.59–4.58) and other
services (AOR, 2.55; 95% CI, 1.59–4.09). For patients who used other services, depression
was associated with 47.2% greater other services expenditure.
Table 5 displays the adjusted OOP healthcare expenditures and percent change associated with
depression from GLM and two-part models stratified by healthcare service types. From the
patients’ perspective, patients with depression had 47.1% and 53% higher medical provider
and other healthcare expenditures, respectively. No significant results were found in inpatient
and other services, which is possibly because of the small sample size.
Discussion
The current study used MCBS data, a nationally representative survey of Medicare
beneficiaries, to estimate the incremental expenditures associated with depression for elderly
breast, lung and prostate cancer patients. In this sample, the depression rate was 18% (19% for
breast, 19% for lung and 16% for prostate). These rates fall in the range of 8% to 24%, which
was estimated from a meta-analysis of depression prevalence among cancer patients assessed
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by diagnostic interviews and self‐report instruments.3 The prevalence rate of 18% in this study
is higher than a previous paper (14%) by Pan et al.11 This is plausible because the previous
paper used International Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) codes to capture clinical diagnosis of depression, while this study used a selfreport instrument. It has been shown that the detection rate of depression is low among cancer
patients and depression is often underdiagnosed because their depression symptoms are
frequently ignored by clinicians and viewed to be a normal psychological reaction of cancer
diagnosis and treatment.25, 26 For example, in a large study of over 1,100 cancer patients,
physicians only correctly identified 33% of patients with mild to moderate depression, and
only 13% of patients with severe depression were diagnosed.26Also, a recent paper found that
depression prevalence was highest by self-reported symptoms scales, followed by diagnostic
interviews and ICD-9-CM codes based on claims databases.27 Depression rates vary broadly
by cancer type and patient age; our study focused on the elderly while previous papers included
adults of all ages and did not distinguish cancer types.
Since the prevalence of self-reported depression is high for elderly cancer patients in this study,
and depression is often unrecognized, it is essential to improve depression screening and
diagnosis for this population. While some instruments such as the Geriatric Depression Scale
(GDS)28 are commonly used to identify depression in the elderly, few studies have assessed
their accuracy in the geriatric cancer setting. Considering the complexity and difficulty to
identify and detect depression for geriatric cancer populations 29, more research is needed to
find or develop accurate, appropriate and validated depression measurement tools.
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Our study found that depression was associated with 34.5% greater adjusted total healthcare
expenditures, which is consistent with a prior study using 2006-2009 Medical Expenditure
Panel Survey data on cancer patients older than 21 years, where the percent increase associated
with depression in total expenditures was about 30%.11 In terms of service subtypes of total
healthcare expenditures, depression was associated with greater adjusted medical provider and
other services expenditures (45.9 % and 50.1%, respectively). Also, depression was associated
with higher likelihood of inpatient services use (AOR=2.94). These findings confirm that
depression is correlated with excess healthcare expenditure and utilization for elderly cancer
patients, and the higher expenditures are concentrated on certain services.
When stratified by payers, depression was associated with 43.8% greater adjusted Medicare
healthcare expenditures, which is higher than a previous paper (about 30%) about elderly
prostate cancer patients from the Medicare perspective

13

. The lower rate identified in that

study may be explained by methodology, as the researchers only focused on prostate cancer
while the current study included two more cancer types, which may have more influence on
the expenditures. When diving deeper into the subtypes, significant findings were found in
medical provider, inpatient and other services, suggesting that, as with total healthcare
expenditures, the excess is mainly attributable to certain services.
From the patients’ perspective, depression was associated with 32.9% higher OOP
expenditures. The OOP expenditures did not include premiums since premiums are separated
from actual spending.17. When expenditures on different service types were analyzed,
significant findings were found for medical provider and other services. These findings stress
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that the excess financial burden of depression is not only placed on the healthcare system but
also on the patients themselves, indicating that comorbid depression can aggravate the personal
financial burden that cancer patients already face.
Subtype analyses from three aspects (i.e., total [all payers], Medicare and OOP expenditures)
all highlighted higher expenditures in the category of medical provider services for elderly
cancer patients with depression. In terms of total and Medicare analyses, depression was
associated with increased inpatient services use. These results are consistent with previous
studies irrespective of cancer diagnosis. For example, two studies of cancer patients using
military and Medicare populations demonstrated that cancer patients with depression had more
hospitalizations.10, 13 Also, depression is associated with increased risk of hospitalization in
patients with heart failure. 30
It is noteworthy that the estimated expenditures from our study can also contribute to the
evaluations of depression-relevant interventions for this population, because the estimates can
be applied in cost-effectiveness studies of interventions addressing depression for elderly
cancer patients: the reduction of depression related healthcare cost would partially offset the
intervention costs.
Since cancer patients with depression incurred substantially higher healthcare utilization and
expenditures from payers’ and patients’ perspectives than their counterparts without
depression, it is possible that managing and treating depression effectively in cancer patients
could improve health outcomes and potentially reduce healthcare expenditures. While
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depression treatment may contribute to higher short-term expenditures (e.g., psychotherapy,
psychotropic medications); expenditures could decrease in the long term. Currently, very few
studies have examined whether depression treatment has an impact on reducing expenditures
in the long-term. One study demonstrated that depression treatment (antidepressants,
psychotherapy and both) increased healthcare expenditures for elderly breast, colorectal and
prostate cancer patients from Medicare’s perspective in the short term but had no effect on
long-term expenditures, however, the study’s follow-up period of two years after depression
diagnosis may not have been long enough31. Encouragingly, studies about patients with other
co-occurring chronic conditions and depression have shown positive results in reducing costs
with depression treatment. For instance, a study about patients with comorbid conditions and
type 2 diabetes mellitus along with depression showed that depression treatment
(antidepressants, psychotherapy and both) decreased healthcare expenditures significantly
during 12 month period after depression diagnosis.32 Another study focusing on patients with
depression and diabetes showed reduced trends for 5-year mean total medical expenditures
when comparing depression collaborative care and usual care.33 Future research needs to
examine whether depression treatment in elderly cancer patients can lower healthcare
expenditures, especially in the long run, from payers’ and patients’ perspectives; the depression
treatment modalities best suited for this often vulnerable population need to be elucidated.
This study has many strengths. It makes a significant contribution to the existing literature by
estimating the healthcare expenditures associated with depression in the elderly cancer
population from payers’ and patients’ perspectives. Also, by examining multiple expenditure
44

categories, our results detail where the excess economic burden of depression originated from
in our study cohort. Additionally, because MCBS data links survey to Medicare fee-for-service
claims, this study adjusted for a comprehensive list of independent variables, including patientlevel health factors that are generally not available in claims data, such as functional status,
general health status and personal health practices. Moreover, this study captured complete
healthcare expenditures including both Medicare and non-Medicare expenditures.
There are some limitations associated with the data and study design. Firstly, some information
such as OOP payments are based on self-report, which may be subject to recall bias. However,
MCBS data is an established principle source for assessing OOP cost for Medicare
beneficiaries, which is a reliable resource for this study.17 Moreover, MCBS includes measures
to minimize recall bias: for example, the respondents are requested to take their facilitating
records of all their healthcare events to the interviews. Secondly, this study is an observational
retrospective cohort study, so the results cannot imply causation. Additionally, this study may
have unmeasured confounding factors that cannot be controlled for. These unmeasured
confounding factors may include cancer severity such as stage at diagnosis, which is not
available in MCBS data. Although depression can happen during any stage of cancer, but many
studies showed a higher prevalence of depression with advanced stage cancer.34, 35 Also, some
studies showed that cancer costs were higher for cancer patients whose stage at diagnosis were
more advanced.36 So the additional healthcare expenditures of depression may be
underestimated.
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Thirdly, the study sample was restricted to fee-for-service Medicare beneficiaries and the
results may not be generalizable to other Medicare beneficiaries.
This study has many important and unprecedented implications. To our best knowledge, it is
the first study to provide a national estimate of depression prevalence in elderly patients with
breast, lung, and prostate cancer, which are the three most common cancer types in the US,
and the excess healthcare cost and utilization burden associated with depression for this
population. This study adds to our understanding of the notable economic burden imposed by
depression on cancer patients. Additionally, our findings reveal the psychological needs of
many elderly cancer patients and their associated higher expenditures; the data may stimulate
interest among many stakeholders including policy makers, clinicians, patients and their
families. Also, the findings highlight the importance of effective depression screening,
diagnosis, treatment and management. In terms of screening and diagnosis, specific
screening/diagnostic criteria need to be implemented with standardized instruments validated
in elderly cancer patients with depression. In terms of depression treatment and management,
more research is needed to investigate whether treating depression has an impact on costreduction over a longer period for both the healthcare system and patients, and to verify the
efficacy of different depression treatments. Additionally, as recommended by other studies, 3739

integrated collaborative care treatment models need to be emphasized in the near future to

monitor and treat depression in cancer patients.
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Conclusions
In this sample of elderly breast, lung and prostate cancer patients, patients with depression
incurred significantly higher healthcare expenditures from payers’ and patients’ perspectives
and across different expenditure types. These findings provide compelling evidence for policy
makers and clinicians to improve depression screening, diagnosis and treatment in geriatric
oncology.
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Table 1.Characteristics of elderly cancer patients by depression status

Characteristics
Total
Year of cancer diagnosis
2007-2009
2010-2012
Gender
Female
Male
Age
65-74
75 and over
Race/ethnicity
Non-Hispanic white
Other
Marital status
Married
Other
Educational attainment
Less than high school
High school
Greater than high school
Poverty status
LT 200% FPL
GE 200% FPL
Supplemental insurance**
Private insurance with Rx
Public insurance with Rx
Medical Insurance only
Other
Cancer site
Breast
Lung

Without
Depression
N
Wt%
582
82.3
Predisposing

With Depression
N
128

Wt %
17.7

317
265

83.9
80.7

63
65

16.1
19.3

234
348

79.5
84.2

56
72

20.5
15.8

177
405

79.4
84

48
80

20.6
16

520
62
Enabling

82.9
76.8

112
16

17.1
23.2

349
233

82.8
81.2

75
53

17.2
18.8

114
213
255

77.9
85.3
81.8

34
39
55

22.1
14.7
18.2

435
147

84.8
74.8

79
47

15.2
25.2

237
53
259
33
Need

83.1
64.2
86.1
81.9

51
27
42
8

16.9
35.8
13.9
18.1

208
67

80.8
80.6

44
19

19.2
19.4

53

Prostate
307
83.7
64
Perceived health status***
Excellent/very good/Good
475
86.4
75
Fair/poor
107
67.3
53
Functional status
limitation***
None
426
84.9
78
≥1
156
64.3
50
Number of comorbid health
conditions**
None or 1
195
88.9
28
>1
387
79.1
100
Personal health practices and use of health services
Smoking Status
Current
38
77.9
11
Past
319
79.9
76
Never
225
86.6
41
BMI
Underweight/normal
206
80.4
54
Overweight
258
83.7
49
Obese/morbid obese
118
82.5
25
External Environment
Metro status
Metropolitan
414
82.5
87
Non-Metropolitan
168
81.5
41

16.3
13.6
32.7
15.1
35.7
11.1
20.9
22.1
20.1
13.4
19.6
16.3
17.5
17.5
18.5

***P < .001, **.001 ≤ P < .01, *.01 ≤ P < .05
Note: Wt%, Weighted percentage; LT, less than; GE, greater than or equal to; FPL, federal
poverty level; Rx, prescription coverage; BMI, body mass index.
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Table 2. Unadjusted healthcare expenditures by depression status
Full sample
In users
Without
With
Without Depression
With Depression
Depression
Depression
(N=582)
(N=128)
Healthcare Expenditures Mean(SE) $ Mean(SE) $ N(%)
Mean(SE)$
N(%)
Mean(SE)$
Total healthcare expenditures
Overall***
44106(2116) 70918(5759)
By service types
Medical provider***
16068(934) 25052(2609)
Hospital outpatient
8050(658)
8006(865)
Prescribed medicine
7891(485)
10188(1242)
Inpatient***
9424(925)
21184(2817) 206(35%) 28743(1890) 77(60%) 35712(3785)
Other*†
2658(237)
6488(1613) 430(74%) 3559(286)
97(76%) 8653(2152)
By payers
Medicare***
28856(1716) 48875(4150)
Out-ofpocket(patient)
6511(291)
9442(1516)
Other third-party
payers
7950(402)
11722(2053) 559(96%) 8232(407)
124(97%) 12031(2099)
Medicare healthcare expenditures
By service types
Medical Provider**
10832(700) 15566(1545)
Hospital outpatient
5766(501)
5949(673)
Inpatient**
8134(842)
17874(2608) 198(34%) 25658(1850) 75(59%) 31072(4458)
Prescribed medicine
3000(375)
5258(1108) 299(51%) 5868(624)
69(54%) 9659(1969)
Other**††
1124(189)
4228(750)
103(18%) 7077(932)
48(38%) 12218(1652)
Out-of-pocket healthcare expenditures
By service types
Medical provider**
1903(122)
3028(348)
Prescribed medicine
1639(98)
1667(189)
Other
2067(158)
4020(1316)
Inpatient
391(117)
320(87)
74(13%) 3290(911)
27(21%) 1685(441)
Hospital outpatient
499(77)
408(113)
359(62%) 823(112)
80(63%) 659(191)
***P < .001, **.001 ≤ P < .01, *.01 ≤ P < .05, indicating significant difference between those
with and without depression among th3 full sample.
†††P < .001, ††.001 ≤ P < .01, †.01 ≤ P < .05, indicating significant difference between those
with and without depression among patients with non-zero expenditures.
Note: SE, Standard Error
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Table 3. Adjusted effect of depression on total healthcare expenditures, overall and
stratified by service types and payers
AOR[95% CI]
Coefficient
$
(SE)
Change % Change
Overall
0.30(0.09)**
11454
34.5
By service types
Medical provider
0.38(0.1)***
8213
45.9
Hospital outpatient
-0.79(0.14)
-617
-7.6
Prescribed medicine
-0.07(0.11)
-217
-6.5
Inpatient‡
2.94[1.82,4.74]*** 0.05(0.11)
1061
5.3
Other‡
1.05[0.65,1.69]
0.41(0.16)*
405
50.1
By Payers
Medicare
0.37(0.1)***
8280
43.8
Out-of-pocket(patient)
0.28(0.13)*
1270
32.9
Other
0.23(0.15)
2613
26.1
***P < .001, **.001 ≤ P < .01, *.01 ≤ P < .05
‡ Because a large number of patients did not have expenditures in these categories of
expenditures, two-part models, with logistic regressions in the first part and GLMs with
gamma distribution and log link in the second part were used to estimate the adjusted
effect of depression.
Note: SE, Standard Error
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Table 4. Adjusted effect of depression on Medicare healthcare expenditures, stratified
by service types
AOR[95% CI]
Coefficient(S
E)
$ Change % Change
Medical provider
0.31(0.1)*
4327
36
Hospital outpatient
-0.02(0.14)
-97
-2.1
Inpatient‡
2.7[1.59,4.58]*** 0.05(0.12)
922
4.8
Prescribed medicine‡ 0.88[0.53,1.46]
-0.07(0.17)
-76
-6.7
Other‡
2.55[1.59,4.09]*
0.39(0.17)*
870
47.2
***P < .001, **.001 ≤ P < .01, *.01 ≤ P < .05
‡ Because a large number of patients did not have expenditures in these categories of
expenditures, two-part models, with logistic regressions in the first part and GLMs with
gamma distribution and log link in the second part were used to estimate the adjusted
effect of depression.
Note: SE, Standard Error
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Table 5. Adjusted effect of depression on out-of-pocket healthcare expenditures,
stratified by service types
AOR [95% CI]
Depression(SE)
$ Change
% Change
Medical provider
0.39(0.16)*
654
47.1
Prescribed medicine
-0.02(0.1)
-10
-2.3
Other
0.43(0.2)*
465
53
Inpatient‡
1.71[0.97,3.01] -0.54(0.35)
-1025
-41.8
Hospital outpatient‡
1.05[0.58,1.92] -0.26(0.22)
-342
-23
***P < .001, **.001 ≤ P < .01, *.01 ≤ P < .05
‡ Because a large number of patients did not have expenditures in these categories of
expenditures, two-part models, with logistic regressions in the first part and GLMs with
gamma distribution and log link in the second part were used to estimate the adjusted
effect of depression.
Note: SE, Standard Error

58

TECHNICAL REPORT OF PROPOSED AIM 3
Depression and high out-of-pocket cost burden among elderly cancer patients
Results
In table 1, the rates of high-out-of-pocket cost burden were compared by depression
status in total and according to predisposing, enabling, need, personal health practices and
use of health services and the external environment factors. Overall, the depressed group was
significantly more likely to have high out-of-pocket cost burden (53% vs 38.12%, p=0.023)
compared to the non-depressed group. When stratified by other covariates, the depressed
group was more likely to have high out-of-pocket cost burden in the groups of males, aged
75 and over years old, other race/ethnicity, other married status, high school, public
insurance with drug, prostate cancer, fair/poor health status, more than one comorbid health
condition, never smokers, underweight/normal and metropolitan.
Table 2 presented the unadjusted effect of depression. The unadjusted effect was
significant with an odds ratio of 1.83 (95% confidence interval: 1.08-3.09,
p=0.024).Compared to the non-depressed group, the odds of having high out-of-pocket cost
burden in the depressed group was 1.83 times that in the non-depressed group.
Table 3 presents the adjusted effect of depression. When controlling for the other
independent variables, the effect became not significant-the adjusted odds ratio was 1.54 and
the 95% confidence interval was 0.86-2.74(p=0.144).
Discussion
In the sample of 710 elderly breast, lung and prostate cancer patients, 128 (18%) reported
depression. In the depressed group 53% had high out-of-pocket cost burden while in the non59

depressed group 38% had. When estimating the relationship between depression and high
out-of-pocket cost burden, the unadjusted effect was significant while the adjusted effect was
not significant and the odds ratio became smaller, from 1.83 to 1.54.
There might be some possible explanations. One possible explanation is that some
covariates were confounders, which were correlated with both depression and high-out-ofpocket cost burden and deflated the true estimate of the relationship. As confounding is a
major threat to internal validity, in the absence of randomization, we used the multivariable
logistic regression to account for their effects to avoid a false positive error. 1, 2
Other reasons can impact the p-values as well. In particular, we suspect that the relatively
small sample size can be a possible explanation. Both the random error and the overall
variability are generally reduced as the sample size increases, which may enable us to detect
even relatively small differences between groups. Our sample size provided power to detect
an OR equal to or greater than 1.83,but was too small to provide a statistically reliable
estimate of the smaller observed adjusted OR of 1.54.3
Additionally, we defined the high out-of-pocket cost burden as the out-of-pocket cost,
excluding insurance premiums, amounted to 10% or more of the person’s annual income.
The 10% threshold is set because previous papers used the same rule4, 5. A recent study also
named it as “underinsurance”, an indicator of the level of patients’ own financial burden.
Moreover, that study defined another indicator - “high total cost burden”, which means the
sum of out-of-pocket cost and the insurance premiums amounting to 20% or more of the
annual income.6 However, there were a lot of missing values in the insurance premiums in
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MCBS data, so we cannot estimate the relationship between depression and high total cost
burden.
Further research using different data sources is needed. Since depression already proved
to increase the financial burden for general elderly in previous studies7, 8 and in cancer
patients in Aim 2 in our study, it is still possible to be associated with high out-of-pocket cost
burden (underinsurance) and/or high total cost burden.
Conclusion
After adjusting for other covariates, depression was not significantly associated with high
out-of-pocket cost burden. Further research is needed to explore the topic about depression
and elderly cancer patients’ financial burden.
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Table 1. Rates of high out-of-pocket cost burden by patients’ characteristics

Characteristics
Total rates
Year of cancer diagnosis
2007-2009
2010-2012
Gender
Female
Male
Age
65-74
75 and over
Race/ethnicity
White
Other
Marital status
Married
Other
Educational attainment
Less than high school
High school
Greater than high school
Poverty status
LT 200% FPL
GE 200% FPL
Supplemental insurance
Private insurance with Rx
Public insurance with Rx
Medical Insurance only
Other
Cancer site
Lung
Breast

Without Depression
95%
Weighted Confidence
Rates
Interval

With Depression
95%
Weighted Confidence
Rates
Interval

38.12

(34.5,41.87)

53

(41.72,63.98) 0.023

37.07
39.16

(31.45-43.05)
(33.74-44.86)

50.29
55.14

(36.58-63.95) 0.079
(39.29-70.02) 0.074

40.26
36.64

(34-46.84)
(31.9-41.65)

49.21
56.59

(35.65-62.89) 0.223
(42.31-69.85) 0.015

37.43
38.56

(30.27-45.18)
(33.77-43.58)

46.35
58.83

(27.77-66.01) 0.415
(47.81-69.02) 0.003

38.57
33.93

(34.66-42.63)
(24.58-44.73)

50.73
67.23

(39.03-62.35) 0.077
(33.34-89.33) 0.045

42.9
29.46

(37.97-47.97)
(23.5-36.22)

54.07
51.25

(38.63-68.77) 0.211
(36.56-65.73) 0.005

41.68
45.27
31.28

(33.07-50.84)
(38.39-52.34)
(26.03-37.06)

50.18
67.35
41.49

(41.1-75.08) 0.079
(49.13-81.5) 0.018
(25.86-59.05) 0.276

34.31
50.76

(30.33-38.53)
(42.19-59.28)

46.36
64.72

(32.18-61.15) 0.141
(47.53-78.79) 0.157

32.34
34.95
42.46
51.24

(26.36-38.96)
(23.22-48.85)
(36.03-49.17)
(31.63-70.48)

48.03
68.98
50.53
43.01

(32.64-63.8)
(45.61-85.5)
(34.02-66.92)
(12.39-80.11)

44.09
41.08

(30.26-58.9)
(34.28-48.24)

72.4
46.04

(49.29-87.63) 0.034
(30.67-62.19) 0.567
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P-Value

0.071
0.013
0.419
0.703

Prostate
Perceived health status
Excellent/very good/Good
Fair/poor
Functional status limitation
0
>=1
Number of comorbid health
conditions
0-1
>1
Smoking Status
Current
Past
Never
BMI
Underweight/normal
Overweight
Obese/morbid obese
Metro status
Metropolitan
Non-Metropolitan

34.69

(29.83-39.88)

53.57

(38.36-68.15) 0.027

33.77
58.53

(29.41-38.41)
(48.72-67.71)

37.28
76.95

(25.53-50.76) 0.638
(62.09-87.19) 0.042

34.31
50.1

(30.09-38.79)
(42.83-57.36)

47.79
61.78

(33.25-62.72) 0.098
(45.55-75.74) 0.187

27.01
43.99

(21.11-33.84)
(38.89-49.22)

35.65
57.34

(17.33-59.42) 0.45
(45.77-68.16) 0.06

39.78
40.14
35.02

(24.69-57.09)
(34.4-46.17)
(28.88-41.71)

49.94
50.32
53.17

(22.21-77.68) 0.55
(38.89-67.22) 0.13
(39.25-66.6) 0.02

28.76
40.1
49.71

(23.17-35.09)
(34.2-46.31)
(41.14-58.29)

46.69
50.86
69.24

(30.7-63.39) 0.016
(36.01-65.56) 0.218
(43.02-87.03) 0.144

34.56
48.1

(30.38-39)
(41.51-54.75)

51.52
56.85

(37.29-65.51) 0.038
(41.36-71.1) 0.341

Note: LT, less than; GE, greater than or equal to; FPL, federal poverty level; Rx, prescription
coverage; BMI, body mass index.
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Table 2. Univariate regression results

Depression (Ref=No)
Yes

Odds ratio
(95% Confidence
Interval)

P-value

1.83(1.08-3.09)

0.024
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Table 3. Multivariable logistic regression modeling of depression and high out-of-cost
burden

Odds ratio
(95% Confidence
Interval)

P-value

Depression (Ref=No)
Yes

1.54(0.86-2.74)

0.144

Year of cancer diagnosis
(Ref=2007-2009)
2010-2012

1.10(0.77-1.58)

0.587

Gender(Ref=Male)
Female

0.88(0.33-2.34)

0.794

1.41 (0.94-2.12)

0.100

Race/ethnicity (Ref= White)
Other race

0.75(0.39-1.45)

0.386

Marital status (Ref=Other)
Married

2.92(1.83-4.69)

0.000

Educational
attainment(Ref=Less than
high school)
High school
Greater than high school

1.55(0.93-2.60)
0.94(0.94-0.57)

0.095
0.79

Poverty Status (Ref=LT
200% FPL)
GE to 200% FPL

0.4(0.24-0.67)

0.001

Supplemental
insurance(Ref= Private
insurance with Rx)
Public insurance with Rx

0.86 (0.39-1.88)

0.697

Age at diagnosis,
(Ref=65-74 years)
75 and over

years
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Medical Insurance only
Other

1.43 (1.00-2.05)
1.40 (0.72-2.74)

Cancer Site(Ref=Lung)
Breast
1.03(0.45-2.39)
Prostate
0.60(0.31-1.17)
Perceived Health Status(Ref=
Excellent/very good/Good)
Fair/Poor
2.69(1.79-4.04)
Functional status
limitation(Ref=0)
At least one

0.052
0.322

0.937
0.133

0.000

1.28(0.86-1.91)

0.224

Number of comorbid health
conditions(Ref=0-1)
1.58(1.06-2.36)
>1

0.024

Smoking Status(Ref=Current)
Past
Never

1.03(0.51-2.10)
1.03(0.49-2.16)

0.930
0.933

BMI(Ref=
Underweight/normal)
Overweight
Obese/morbid obese

1.52(1.01-2.29)
2.03(1.24-3.30)

0.046
0.005

Metro
Status(Ref=Metropolitan)
Non-Metropolitan

1.41(0.98-2.03)

0.060

Note: LT, less than; GE, greater than or equal to; FPL, federal poverty level; Rx, prescription
coverage; BMI, body mass index.
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